SLAMF7 and plasma cell myeloma: Following the demonstration of promising preclinical and clinical activities [34,35,36], two monoclonal antibodies targeting CD38 (daratumumab) [37] and SLAMF7 (elotuzumab) [38] were approved by the Food and Drug Administration (FDA) to treat patients with relapsed and refractory multiple myeloma in late 2015.